Beam Global — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Beam Global filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.24M | Apr 9, 2026 |
| FY2025 | Dec 31, 2024 | $49.34M | Apr 9, 2026 |
| FY2024 | Dec 31, 2023 | $67.35M | Apr 11, 2025 |
| FY2022 | Dec 31, 2022 | $22.00M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $9.00M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $6.21M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $5.11M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $6.16M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.41M | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | $2.78M | Apr 2, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.52M | Apr 9, 2026 |
| FY2025 | Dec 31, 2024 | $7.30M | Apr 9, 2026 |
| FY2024 | Dec 31, 2023 | $1.20M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | ($1.67M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($972.0K) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($711.0K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($153.8K) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($192.1K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($472.8K) | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | ($144.7K) | Apr 2, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($27.00M) | Apr 9, 2026 |
| FY2025 | Dec 31, 2024 | ($11.28M) | Apr 9, 2026 |
| FY2024 | Dec 31, 2023 | ($16.06M) | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | ($19.68M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($6.60M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($5.21M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($3.93M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($3.60M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($3.04M) | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | ($2.63M) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($27.53M) | Apr 9, 2026 |
| FY2025 | Dec 31, 2024 | ($11.66M) | Apr 9, 2026 |
| FY2024 | Dec 31, 2023 | ($16.26M) | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | ($19.72M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($6.60M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($5.21M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($3.27M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($2.53M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($2.70M) | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | ($2.79M) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $600.0K | Apr 9, 2026 |
| FY2025 | Dec 31, 2024 | $1.80M | Apr 9, 2026 |
| FY2024 | Dec 31, 2023 | $2.30M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $1.20M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $400.00M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $261.6K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $412.6K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $164.1K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.8K | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | $3.5K | Apr 2, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.48M) | Apr 9, 2026 |
| FY2025 | Dec 31, 2024 | ($2.19M) | Apr 9, 2026 |
| FY2024 | Dec 31, 2023 | ($13.31M) | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | ($18.11M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($6.41M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($4.14M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($4.83M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($712.5K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($3.44M) | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | ($1.80M) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $418.0K | Apr 9, 2026 |
| FY2025 | Dec 31, 2024 | $828.0K | Apr 9, 2026 |
| FY2024 | Dec 31, 2023 | $937.0K | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $872.0K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $498.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $265.8K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $32.8K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $23.5K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $23.9K | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | $115.9K | Apr 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.73M | Apr 9, 2026 |
| FY2025 | Dec 31, 2024 | $61.46M | Apr 9, 2026 |
| FY2024 | Dec 31, 2023 | $77.64M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $37.73M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $30.66M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $32.90M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $7.29M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $3.49M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $3.24M | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | $2.06M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.89M | Apr 9, 2026 |
| FY2025 | Dec 31, 2024 | $20.17M | Apr 9, 2026 |
| FY2024 | Dec 31, 2023 | $28.10M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $14.52M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $4.68M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.75M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.46M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $5.97M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $3.59M | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | $3.44M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.85M | Apr 9, 2026 |
| FY2025 | Dec 31, 2024 | $41.29M | Apr 9, 2026 |
| FY2025 | Dec 31, 2023 | $49.54M | Apr 9, 2026 |
| FY2024 | Dec 31, 2022 | $23.21M | Apr 11, 2025 |
| FY2023 | Dec 31, 2021 | $25.98M | Apr 16, 2024 |
| FY2022 | Dec 31, 2020 | $29.15M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $5.82M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | ($2.48M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | ($349.3K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | ($1.39M) | Mar 20, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Apr 9, 2026 |
| FY2025 | Dec 31, 2024 | $10.58M | Apr 9, 2026 |
| FY2025 | Dec 31, 2023 | $10.27M | Apr 9, 2026 |
| FY2024 | Dec 31, 2022 | $4.60M | Apr 11, 2025 |
| FY2022 | Dec 31, 2021 | $0 | Mar 31, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($131.65M) | Apr 9, 2026 |
| FY2025 | Dec 31, 2024 | ($104.64M) | Apr 9, 2026 |
| FY2024 | Dec 31, 2023 | ($93.36M) | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | ($77.30M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($57.62M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($51.02M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($45.81M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($41.88M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($38.28M) | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | ($35.24M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $969.0K | Apr 9, 2026 |
| FY2025 | Dec 31, 2024 | $4.57M | Apr 9, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Apr 9, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 9, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 11, 2025 |
| FY2024 | Dec 31, 2023 | (1) | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 19.12M | Apr 9, 2026 |
| FY2025 | Dec 31, 2024 | 14.84M | Apr 9, 2026 |
| FY2024 | Dec 31, 2023 | 14.40M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | 10.18B | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 8.97B | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 8.48M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 5.21M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 2.91M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 141.84M | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | 120.11M | Apr 2, 2018 |